Ignite Creation Date:
2024-05-06 @ 9:54 AM
Last Modification Date:
2024-10-26 @ 12:21 PM
Study NCT ID:
NCT03109717
Status:
COMPLETED
Last Update Posted:
2021-06-18
First Post:
2017-03-01
Brief Title:
Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression
Sponsor:
Kathryn OConnor
Organization:
The Cleveland Clinic
Study Overview
Official Title:
Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression
Status:
COMPLETED
Status Verified Date:
2021-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MAOI
Brief Summary:
Study TRD subjects resistance to at least 2 different antidepressants we hypothesize that because of their significant depression and treatment resistant status they are most likely to exhibit BSMN pathway abnormalities
Detailed Description:
Potential subjects will be identified during clinical visits If a patient qualifies to participate in the study they will have to stop any antidepressants that they are taking to prepare for the use of MAOIs After a two week washout period subjects will have an fMRI and will be started on a MAOI They will then be followed up for 8 weeks which is routine and considered standard care
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None